Long-Term Prognostic Impact of the Use of Erythropoietic-Stimulating Agents in Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Imatinib

Lignende værker

• Homoharringtonine with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia
  af: Maiti, Abhishek, et al.
  Udgivet: (2017)
• Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
  af: Jabbour, Elias, et al.
  Udgivet: (2008)
• Dasatinib Early Intervention After Cytogenetic or Hematologic Resistance to Imatinib in Patients With Chronic Myeloid Leukemia
  af: Quintás-Cardama, Alfonso, et al.
  Udgivet: (2009)
• Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in the Long-Term Outcome of Patients With Early Chronic Myeloid Leukemia in Chronic Phase
  af: Alvarado, Yesid, et al.
  Udgivet: (2009)
• Pilot study of Bortezomib for Patients with Imatinib-Refractory Chronic Myeloid Leukemia in Chronic or Accelerated Phase
  af: Santos, Fabio P S, et al.
  Udgivet: (2011)